Skip to main content

Cosciens Biopharma Inc(CSCI-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.95
Day High2.14
Open:1.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Cosciens Biopharma Inc

Select a category then submit the form to load news
GlobeNewswire
COSCIENS Provides Strategic Update
Newsfile
Upcoming Meeting Dates - February 23, 2026
GlobeNewswire
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
GlobeNewswire
COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update
GlobeNewswire
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
GlobeNewswire
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
Newswire.ca
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
GlobeNewswire
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
GlobeNewswire
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
Newsfile
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Healthcare Sector Stocks on TSX (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Healthcare Sector Stocks on TSX (CSCI)
GlobeNewswire
COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
GlobeNewswire
COSCIENS Biopharma Announces Change to Board of Directors
GlobeNewswire
COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
GlobeNewswire
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
AI-generated - The Globe and Mail
Cosciens Biopharma: Top 10 Undervalued Biotechnology Industry Stocks (CSCI)
GlobeNewswire
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
GlobeNewswire
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Profile

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology. The Company has two reportable and operating segments: Active ingredient and Biopharmaceutical.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.